Abbott presented late-breaking clinical data at the Heart Rhythm Society 2026. This showcase highlights new evidence for its pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios. These portfolios aim to treat heart rhythm disorders. Data included six-month results from the FlexPulse IDE study for the TactiFlex Duo Ablation Catheter, Sensor Enabled. The company also presented evidence for posterior wall ablation with the Volt PFA System.
New Clinical Evidence
Research for the UltiSynq CSP implantable cardioverter-defibrillator (ICD) lead, and the investigational AVEIR CSP leadless pacemaker system was also presented. The FlexPulse IDE study results showed 87% of patients were free from documented arrhythmias. Additionally, 98.3% of patients had no major safety events.
“The Abbott TactiFlex Duo catheter offers the convenience of seamlessly switching treatment between radiofrequency and pulsed field ablation based upon the patient’s anatomy and their personalized ablation plan,” said Jonathan P. Piccini, M.D., professor of medicine, Duke University Medical Center, who presented the late-breaking data at HRS. “While RF has long been a well-established ablation approach, with this study, we have been able to show that the TactiFlex Duo’s point-to-point PFA is an effective approach for a significant number of our patients.”
“Physicians are increasingly using left bundle area pacing for pacemaker patients, because it is associated with improved physiological activation compared with traditional pacing on the right side of the heart. The data from the ASCEND trial show that an ICD lead designed for physiologic pacing can support restoration of normal heart rhythms when placed in the left bundle branch area. These early results suggest the potential to extend the benefits of physiologic pacing to ICD patients in an efficient manner,” said Rahul N. Doshi, M.D., FHRS, FACC, professor of medicine at Arizona State University.
New Volt PFA System data confirms freedom from AFib recurrence
Late-breaking six-month data from the Volt CE Mark Extension Cohort trial demonstrated positive outcomes for patients in which the posterior wall of the heart was treated in addition to the standard treatment.
“Treating abnormal heart rhythms is not a siloed or one-size-fits-all approach, which is why Abbott is creating a holistic cardiovascular portfolio that empowers physicians to care for a wide range of arrhythmias,” said Priya Jagasia, divisional vice president of regulatory, clinical, reimbursement, and strategic initiatives at Abbott.“The data from these clinical trials serve as a cornerstone for the innovations we’re developing to help people live healthier lives.”
The Volt CE Mark Extension Cohort trial data showed that the Volt PFA System is efficient. It uses fewer therapy applications compared to other systems. Additionally, the ASCEND CSP IDE trial evaluated the UltiSynq CSP lead. The trial met its primary safety and effectiveness endpoints at three months. These findings provide physicians with evidence-based solutions to treat complex patient cases. Abbott remains focused on developing life-changing technologies to help patients live more fully.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: PRNewswire.com
